Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor-positive Advanced Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT02003209
What this trial is testing

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Who this might be right for
HER2-Positive Breast CarcinomaHormone Receptor-Positive Breast CarcinomaStage IB Breast Cancer AJCC v7+5 more
National Cancer Institute (NCI) 315
Testing effectiveness (Phase 2)Study completedNCT03671330
What this trial is testing

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 327
Post-approval studies (Phase 4)UnknownNCT05191914
What this trial is testing

Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors

Who this might be right for
Breast Cancer
Liaoning Cancer Hospital & Institute 20
Testing effectiveness (Phase 2)Looking for participantsNCT07558733
What this trial is testing

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Who this might be right for
HR+ HER2- Breast Cancer
Faeth Therapeutics 32
Not applicableLooking for participantsNCT07073755
What this trial is testing

Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd

Who this might be right for
Metastatic Breast CancerDrug ResistanceHormone Receptor-Positive Breast Cancer+3 more
Hunan Cancer Hospital 200
Testing effectiveness (Phase 2)Study completedNCT02404844
What this trial is testing

Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer

Who this might be right for
Breast Cancer
University Hospital, Essen 48
Early research (Phase 1)Study completedNCT04925284
What this trial is testing

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Who this might be right for
Non Small Cell Lung CancerCervical CancerSCCHN+8 more
Exelixis 269
Testing effectiveness (Phase 2)Study completedNCT00626106
What this trial is testing

QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast CancerBreast TumorsMetastatic Cancer
NantCell, Inc. 156
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07619066
What this trial is testing

A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.

Who this might be right for
Advanced Breast CancerHormone Receptor Positive / HER2-negative Breast CancerHER2 Mutation
MedSIR 25
Early research (Phase 1)Study completedNCT04483505
What this trial is testing

Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.

Who this might be right for
Breast Cancer MetastaticHormone Receptor Positive Malignant Neoplasm of Breast
Fundacion CRIS de Investigación para Vencer el Cáncer 9
Testing effectiveness (Phase 2)Ended earlyNCT06851442
What this trial is testing

Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 8
Early research (Phase 1)Study completedNCT00328120
What this trial is testing

Faslodex 500mg Multiple Dose Tolerability Study in BC Patients

Who this might be right for
Advanced Breast Cancer
AstraZeneca 20
Testing effectiveness (Phase 2)Study completedNCT02291913
What this trial is testing

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
SCRI Development Innovations, LLC 48
Large-scale testing (Phase 3)Looking for participantsNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Early research (Phase 1)Active Not RecruitingNCT03332797
What this trial is testing

GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 181
Testing effectiveness (Phase 2)Looking for participantsNCT06993844
What this trial is testing

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsAdvanced Breast Cancer
Ensem Therapeutics 233
Early research (Phase 1)Looking for participantsNCT05283330
What this trial is testing

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Who this might be right for
Cervical CancerBreast CancerColon Cancer+4 more
Orano Med Theranostics, SAS 48
Testing effectiveness (Phase 2)WithdrawnNCT06105008
What this trial is testing

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
RemeGen Co., Ltd.
Testing effectiveness (Phase 2)Looking for participantsNCT05735080
What this trial is testing

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Who this might be right for
Breast CancerBreast Cancer MetastaticHormone Receptor Positive Tumor+6 more
Incyclix Bio 150
Not applicableStudy completedNCT00735215
What this trial is testing

Faslodex Registry: Fulvestrant in Current Clinical Practice

Who this might be right for
Metastatic Breast Cancer
AstraZeneca 200
Next Page